Press Release

February 4, 2005

ContraVac, Inc. announced the successful completion of its first capital financing, a $1,500,000 private placement offering of preferred stock that closed on February 4, 2005. The Charlottesville biotechnology company's stock offering was subscribed to by local and mid-Atlantic angel investors with the Piedmont Angel Network in Greensboro, N.C. taking a lead role. ContraVac is a University of Virginia company spun-out of the Center for Research in Contraceptive and Reproductive Health in the Department of Cell Biology. ContraVac has licensed patents from the University of Virginia Patents Foundation for the use of specific proteins found in the human testis for detecting and measuring human sperm. The patents have led to the development of the first home immunodiagnostic tests for sperm, SpermCheck¬. These tests will be used by infertile men, recently vasectomized men and men taking male contraceptives

"I am encouraged by the confidence that the investment community has shown in our technology," reported ContraVac founder Professor John C. Herr, in whose lab the technology was developed. "Previous investments by the Center for Innovative Technology in research and by the Patents Foundation to establish strong patent positions have led to the capitalization of this effort. These early investments in intellectual property have been central to our efforts."

ContraVac intends to introduce SpermCheck Vasectomy, the first device in the SpermCheck product line, in the fourth quarter of 2005. According to Ed Leary, President and CFO, "We anticipate that the successful completion of this financing will enable ContraVac to obtain FDA approval and commercialization of SpermCheck Vasectomy." ContraVac is located in the Spinner Technologies Incubator Laboratory on the grounds of the University of Virginia and its motto is: "The Company Putting the Science of Reproduction to Work."